NVO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the company's obesity treatment study results [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Moon v. Novo Nordisk A/S and covers purchasers of Novo Nordisk securities from November 2, 2022, to December 19, 2024 [1]. - Investors have until March 25, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Novo Nordisk executives made false statements about the success of the phase 3 CagriSema study, specifically regarding weight loss outcomes and dosage tolerability [3]. Group 2: Allegations Against Novo Nordisk - The lawsuit alleges that Novo Nordisk misrepresented the reliability of information regarding the CagriSema study's outcomes and failed to disclose critical details about dosage tolerability [3]. - It is claimed that the optimistic projections of achieving at least 25% weight loss were not met, and the study's flexible protocol limited the ability to provide accurate weight loss data [3]. - Following the release of the study results on December 20, 2024, Novo Nordisk's stock price fell nearly 18%, indicating a significant market reaction to the disclosed information [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Novo Nordisk securities during the class period to seek lead plaintiff status [5]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud cases, having recovered $6.6 billion for investors in related class action cases [6].